AbCellera Biologics Inc. (ABCL) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $5.67 (-0.26%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 5, 2024 | Gary Nachman | BMO Capital | $5.00 | -11.8% |
| Aug 23, 2024 | Scott Schoenhaus | KeyBanc | $5.00 | -11.8% |
| May 8, 2024 | Scott Schoenhaus | KeyBanc | $7.00 | +23.5% |
| Dec 15, 2022 | Andrea Tan | Goldman Sachs | $30.00 | +429.1% |
Top Analysts Covering ABCL
ABCL vs Sector & Market
| Metric | ABCL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +39.8% | +16366.1% | +18.0% |
| P/E Ratio | -8.50 | 3.02 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $7M | $8M | $11M | 2 |
| 2026-12-31 | $8M | $9M | $12M | 2 |
| 2027-03-31 | $5M | $6M | $9M | 2 |
| 2027-06-30 | $6M | $7M | $10M | 2 |
| 2027-09-30 | $7M | $8M | $11M | 2 |
| 2027-12-31 | $8M | $10M | $13M | 2 |
| 2028-12-31 | $34M | $52M | $90M | 4 |
| 2029-12-31 | $44M | $66M | $114M | 3 |
| 2030-12-31 | $68M | $102M | $178M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.25 | $-0.17 | $-0.14 | 1 |
| 2026-12-31 | $-0.25 | $-0.17 | $-0.14 | 1 |
| 2027-03-31 | $-0.34 | $-0.24 | $-0.19 | 1 |
| 2027-06-30 | $-0.34 | $-0.24 | $-0.19 | 1 |
| 2027-09-30 | $-0.33 | $-0.23 | $-0.18 | 1 |
| 2027-12-31 | $-0.33 | $-0.23 | $-0.18 | 1 |
| 2028-12-31 | $-0.88 | $-0.79 | $-0.67 | 4 |
| 2029-12-31 | $-1.47 | $-0.75 | $-0.42 | 2 |
| 2030-12-31 | $-1.27 | $-0.64 | $-0.36 | 2 |
Frequently Asked Questions
What is the analyst consensus for ABCL?
The consensus among 1 analysts covering AbCellera Biologics Inc. (ABCL) is Buy with an average price target of $7.50.
What is the highest price target for ABCL?
The highest price target for ABCL is $30.00, set by Andrea Tan at Goldman Sachs on 2022-12-15.
What is the lowest price target for ABCL?
The lowest price target for ABCL is $5.00, set by Scott Schoenhaus at KeyBanc on 2024-08-23.
How many analysts cover ABCL?
1 analysts have issued ratings for AbCellera Biologics Inc. in the past 12 months.
Is ABCL a buy or sell right now?
Based on 1 analyst ratings, ABCL has a consensus rating of Buy (2.00/5) with a +39.8% upside to the consensus target of $7.50.
What are the earnings estimates for ABCL?
Analysts estimate ABCL will report EPS of $-0.17 for the period ending 2026-09-30, with revenue estimated at $8M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.